Brickell Biotech, Inc. (BBI)
| Market Cap | 58.48M |
| Revenue (ttm) | 793,000 |
| Net Income (ttm) | -25.82M |
| Shares Out | 61.16M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $0.679 |
| Previous Close | $0.689 |
| Change ($) | -0.010 |
| Change (%) | -1.44% |
| Day's Open | 0.689 |
| Day's Range | 0.670 - 0.700 |
| Day's Volume | 906,027 |
| 52-Week Range | 0.466 - 1.700 |
Brickell Biotech (NASDAQ: BBI) shares are trading lower after the company announced a bought deal offering of common stock of $5 million, which was later increased to $7 million. Brickell Biotech is a c...
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and different...
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differe...
Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021 Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021
BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
Brickell (BBI) delivered earnings and revenue surprises of -25.00% and -83.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Brickell Biotech (NASDAQ:BBI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.15), which m...
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies exp...
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescrip...
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021
Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Inf...
Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment
BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differ...
Brickell (BBI) delivered earnings and revenue surprises of -87.50% and -97.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis
Webinar taking place on Friday, March 26th @ 10 am EDT Webinar taking place on Friday, March 26th @ 10 am EDT
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kaken Pharmac...
Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbursement pri...
BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript
Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pivotal Phas...
BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...
Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S .
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescr...
Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan Advancement of the U.S. based program will be dependent upon resu...
Claims directed to novel crystalline forms of sofpironium bromide
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript
Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel ...
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...
BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...
Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2020 Results - Earnings Call Transcript
Announces top-line results from 12-month, Phase 3, long-term safety study Announces top-line results from 12-month, Phase 3, long-term safety study
SFC (formerly known as Startup Funding Club – a UK a seed stage investor – has received £10 million from British Business Investments (the commercial subsidiary of the British Business Bank), to deploy ...
Brickell Biotech, Inc. (BBI) CEO Rob Brown on Q4 2019 Results - Earnings Call Transcript
Shares of Brickell Biotech Inc. BBI, +60.86% were vaulted 61% higher on very heavy volume, putting them on track for the biggest one-day gain since the biopharmaceutical company went public 27 years ago...
Shares of thinly traded nano-cap biotech Brickell Biotech Inc (NASDAQ: BBI) are skyrocketing on above-average volume Thursday.
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...
BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing inno...
BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...
About BBI
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Bou... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Robert Brown | Employees 13 |
| Stock Exchange NASDAQ | Ticker Symbol BBI |
Financial Performance
In 2020, BBI's revenue was $1.82 million, a decrease of -76.99% compared to the previous year's $7.92 million. Losses were -$20.91 million, -12.41% less than in 2019.